Brief: Immunocore Says Tebentafusp Showed Improvement In Overall Survival As First-Line Treatment In mUM

Immunocore Holdings

12/04/2021 21:34

April 12 (Reuters) - Immunocore Holdings PLC  IMCR.O :
    * IMMUNOCORE HOLDINGS - TEBENTAFUSP SHOWED STATISTICALLY
SIGNIFICANT & CLINICALLY MEANINGFUL IMPROVEMENT IN OVERALL
SURVIVAL AS FIRST-LINE TREATMENT IN MUM
    * IMMUNOCORE HOLDINGS PLC - TREATMENT-RELATED ADVERSE EVENTS
WERE
MANAGEABLE AND CONSISTENT WITH PROPOSED MECHANISM IN  PHASE 3
STUDY

Source text for Eikon:  ID:nGNE6SgR5P 
Further company coverage:  IMCR.O 

 ((Reuters.Briefs@thomsonreuters.com;))